2143P - Mortality within 30 days after last dose of intravenous systemic anti-cancer therapy: Single-center, one-year, retrospective analysis

Background

Mortality within 30 days of systemic anti-cancer therapy may be a useful indicator of the preventable harm to patients from systemic anti-cancer therapy, but data on this indicator are limited. Identifying the characteristics of patients who develop mortality within 30 days after treatment will contribute to improving the quality of patient care and reducing financial toxicity. In this study, we aimed to screen the patients who received systemic treatment in our center in 2022 and to determine the 30-day mortality rate after the last treatment dose.

Methods

The data of all patients who received intravenous systemic anti-cancer therapy in our center in 2022 were reviewed retrospectively. Diagnoses, disease stages, chemotherapy regimens, and patient characteristics were recorded. 30-day mortality was defined as death within the first 30 days after receiving the last treatment dose.

Results

A total of 1937 patients were included in the study. The majority of the patients (n = 595, 30.7%) had gastrointestinal system cancers, followed by breast cancer (n = 369, 19.1%) and lung cancer (n = 357, 18.5%). When the patients' last treatments were reviewed, chemotherapy was the most common (n = 1514, 78.1%), followed by chemotherapy-monoclonal antibody combination (n = 241, 12.4%), and immunotherapy monotherapy (n = 91, 4.7%). The 30-day mortality rate after systemic anticancer treatment was 7.0% (n = 136) in the entire patient group. While the 30-day mortality rate for patients who received chemotherapy was 7.2% (110/1514), the mortality rate for patients who received immunotherapy (combined with chemotherapy or monotherapy) was 14.4% (15/104).

Conclusions

Our findings show that the 30-day mortality rate is high, especially in certain cancer types and after immunotherapy. In this patient group, it is necessary to review the treatment decision-making process before giving treatments with unclear clinical benefits. In addition, it is necessary to repeat our results in groups where disease types, disease stages, and treatment lines are homogeneous.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.